The effect of Mycobacterium tuberculosis treatment on thrombelastography-assessed haemostasis: a prospective cohort study.

IF 2.6 4区医学 Q2 HEMATOLOGY

Thrombosis Journal Pub Date : 2024-06-26 DOI:10.1186/s12959-024-00625-4

Hans Johan Niklas Lorentsson, Christina R Clausen, Daniel Faurholt-Jepsen, Katrine Bagge Hansen, Sidse Graff Jensen, Rikke Krogh-Madsen, Per G Hagelqvist, Pär I Johansson, Tina Vilsbøll, Filip K Knop, Pernille Ravn

{"title":"The effect of Mycobacterium tuberculosis treatment on thrombelastography-assessed haemostasis: a prospective cohort study.","authors":"Hans Johan Niklas Lorentsson, Christina R Clausen, Daniel Faurholt-Jepsen, Katrine Bagge Hansen, Sidse Graff Jensen, Rikke Krogh-Madsen, Per G Hagelqvist, Pär I Johansson, Tina Vilsbøll, Filip K Knop, Pernille Ravn","doi":"10.1186/s12959-024-00625-4","DOIUrl":null,"url":null,"abstract":"Background and objective: Tuberculosis disease (TB) and tuberculosis infection (TBI) have been associated with increased risk of cardiovascular disease which may be connected to infection-related haemostatic changes. It is unknown if treatment of Mycobacterium tuberculosis influences haemostasis. Here, we assessed if TB or TBI treatment affects thrombelastography (TEG)-assessed haemostasis.Methods: Individuals with TB or TBI were included from a TB outpatient clinic in Copenhagen, Denmark. Patients treated with antithrombotic medication or systemic immunosuppressants were excluded. TEG analysis was performed before and after TB/TBI treatment using the TEG®6s analyser to provide data on the reaction time of clot initiation (R) (min), the speed of clot formation (K) (min) and clot build-up (Angle) (°), maximum clot strength (MA) (mm), and clot breakdown/fibrinolysis (LY30) (%). Differences in TEG were assessed using paired t tests.Results: We included eleven individuals with TB with median [interquartile range] [IQR] age 52 (Liu et al. in Medicine (United States) 95, 2016) years and mean (standard deviation) (SD) body mass index (BMI) 24.7 (6.3) kg/m2 as well as 15 individuals with TBI with median [IQR] age 49 (Wells et al. in Am J Respir Crit Care Med 204:583, 2021) years and BMI 26.0 (3.2) kg/m2. Treatment reduced MA for both TB (64.0 (6.3) vs. 57.9 (5.2) mm, p = 0.016) and TBI (61.3 (4.1) vs. 58.6 (5.0) mm, p = 0.023) whereas R, K, Angle and LY30 were unaffected.Conclusion: TEG analysis showed that treatments of TB and TBI were associated with reduced MA which may indicate the existence of cardiovascular benefits from therapy.Trial registration: Registered at ClinicalTrials.gov 05 April 2021 with registration number NCT04830462.","PeriodicalId":22982,"journal":{"name":"Thrombosis Journal","volume":"22 1","pages":"54"},"PeriodicalIF":2.6000,"publicationDate":"2024-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11201340/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Thrombosis Journal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12959-024-00625-4","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background and objective: Tuberculosis disease (TB) and tuberculosis infection (TBI) have been associated with increased risk of cardiovascular disease which may be connected to infection-related haemostatic changes. It is unknown if treatment of Mycobacterium tuberculosis influences haemostasis. Here, we assessed if TB or TBI treatment affects thrombelastography (TEG)-assessed haemostasis.

Methods: Individuals with TB or TBI were included from a TB outpatient clinic in Copenhagen, Denmark. Patients treated with antithrombotic medication or systemic immunosuppressants were excluded. TEG analysis was performed before and after TB/TBI treatment using the TEG^®6s analyser to provide data on the reaction time of clot initiation (R) (min), the speed of clot formation (K) (min) and clot build-up (Angle) (°), maximum clot strength (MA) (mm), and clot breakdown/fibrinolysis (LY30) (%). Differences in TEG were assessed using paired t tests.

Results: We included eleven individuals with TB with median [interquartile range] [IQR] age 52 (Liu et al. in Medicine (United States) 95, 2016) years and mean (standard deviation) (SD) body mass index (BMI) 24.7 (6.3) kg/m² as well as 15 individuals with TBI with median [IQR] age 49 (Wells et al. in Am J Respir Crit Care Med 204:583, 2021) years and BMI 26.0 (3.2) kg/m². Treatment reduced MA for both TB (64.0 (6.3) vs. 57.9 (5.2) mm, p = 0.016) and TBI (61.3 (4.1) vs. 58.6 (5.0) mm, p = 0.023) whereas R, K, Angle and LY30 were unaffected.

Conclusion: TEG analysis showed that treatments of TB and TBI were associated with reduced MA which may indicate the existence of cardiovascular benefits from therapy.

Trial registration: Registered at ClinicalTrials.gov 05 April 2021 with registration number NCT04830462.

查看原文本刊更多论文

结核分枝杆菌治疗对血栓弹性成像评估止血效果的影响：一项前瞻性队列研究。

背景和目的：结核病（TB）和结核感染（TBI）与心血管疾病风险增加有关，这可能与感染相关的止血变化有关。目前尚不清楚结核分枝杆菌的治疗是否会影响止血。在此，我们评估了结核病或创伤性脑损伤治疗是否会影响血栓弹力图（TEG）评估的止血功能：方法：从丹麦哥本哈根的一家结核病门诊中纳入结核病或创伤性脑损伤患者。使用抗血栓药物或全身性免疫抑制剂治疗的患者除外。在 TB/TBI 治疗前后使用 TEG®6s 分析仪进行了 TEG 分析，以提供以下数据：血块形成的反应时间 (R) (分钟)、血块形成的速度 (K) (分钟) 和血块形成的角度 (°)、最大血块强度 (MA) (mm) 和血块分解/纤溶 (LY30) (%)。采用配对 t 检验评估 TEG 的差异：我们纳入了 11 名结核病患者，他们的中位数[四分位距][IQR]年龄为 52 岁（Liu 等人，发表于《医学（美国）》95，2016 年），平均（标准差）体重指数（BMI）为 24.7 (6.3) kg/m2；还纳入了 15 名创伤性脑损伤患者，他们的中位数[IQR]年龄为 49 岁（Wells 等人，发表于《Am J Respir Crit Care Med》204:583，2021 年），体重指数（BMI）为 26.0 (3.2) kg/m2。结核病（64.0 (6.3) vs. 57.9 (5.2) mm，p = 0.016）和创伤性脑损伤（61.3 (4.1) vs. 58.6 (5.0) mm，p = 0.023）的治疗均可减少 MA，而 R、K、Angle 和 LY30 则不受影响：TEG分析表明，结核病和创伤性脑损伤的治疗与MA的降低有关，这可能表明治疗对心血管有益：该试验已于 2021 年 4 月 5 日在 ClinicalTrials.gov 注册，注册号为 NCT04830462。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Thrombosis Journal Medicine-Hematology

CiteScore

3.80

自引率

3.20%

发文量

审稿时长

16 weeks

期刊介绍： Thrombosis Journal is an open-access journal that publishes original articles on aspects of clinical and basic research, new methodology, case reports and reviews in the areas of thrombosis. Topics of particular interest include the diagnosis of arterial and venous thrombosis, new antithrombotic treatments, new developments in the understanding, diagnosis and treatments of atherosclerotic vessel disease, relations between haemostasis and vascular disease, hypertension, diabetes, immunology and obesity.